Details for Patent: 9,447,106
✉ Email this page to a colleague
Which drugs does patent 9,447,106 protect, and when does it expire?
Patent 9,447,106 protects BRUKINSA and is included in one NDA.
This patent has thirty-two patent family members in twenty-six countries.
Summary for Patent: 9,447,106
| Title: | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
| Abstract: | The invention is substituted 4,5-dihydro- and 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrimidine compounds of formula (I), ##STR00001## and salts thereof, compositions thereof, and methods of use therefor, such as inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. |
| Inventor(s): | Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN) |
| Assignee: | BeiGene, Ltd. (George Town, KY) |
| Application Number: | 14/723,417 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 9,447,106
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Sign Up | ||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA | ⤷ Sign Up | ||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,447,106
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2989106 | ⤷ Sign Up | 301161 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2989106 | ⤷ Sign Up | PA2022504 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2989106 | ⤷ Sign Up | LUC00250 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
